Glycobond was founded in 2011 as a spin-off from research performed at Linköping University, Sweden. The company’s first product is an assay for HCC diagnosis, HepaCheC®. Glycobond’s focus is in the field of liver disease and cancer, utilizing recombinant technology for production of carbohydrate-binding peptides with defined specificities for use in detection of aberrant glycosylation upon disease development. The company’s first developed recombinant peptide, Mono-F, has shown unique and innovative properties and has received patent protection in several countries.
Board of directors
Stefan Eschbach has a PhD from University of Freiburg and has more than 25 years of experience in the international Life Science industry. He is the former Executive Vice President and General Manager of Phadia and has more than 10 years of experience being responsible for business units, R&D, production and sales in Pharmacia Diagnostics, Pharmacia & Upjohn Diagnostics and Elias Entwicklungslabor fur immunoassays GmbH/Elias Medizintechnik GmbH. Today, Stefan is a private investor in several med-tech and Life Science companies.
Stefan has served as Chairman of the Board of Glycobond since 2015.
Peter Påhlsson has more than 25 years’ experience in medical biochemistry and glycobiology with a PhD from Lund University. He was appointed Professor in in Medical Biology, Chemical Diagnostics at Linköping University at Linköping University, in 2006. He has published more than 60 publications in peer-reviewed journals in the field of glycobiology and clinical biochemistry and supervised 6 doctoral students.
Peter has served as CEO and board member of Glycobond since 2011
Ingvar Rydén obtained his M.D. from Lund University in 1991. He was awarded a Ph.D. in clinical chemistry from Linköping University, in 2002 and became an associate professor at Linköping University, Sweden, in 2014. He has worked as a physician with a specialization in clinical chemistry at Kalmar County Hospital for nearly two decades. During 2010 -2016 he was the Senior Medical Advisor at Roche Diagnostics Scandinavia AB, working closely with the Strategic Marketing and Medical Affairs teams, focusing on oncology, cardiology, neurotrauma and infectious diseases. He is now a full time Senior Lecturer/Associate Professor at Linköping University
Ingvar has served as board member of Glycobond since 2011
Bengt-Harald Jonsson obtained his PhD in Chemistry/Biochemistry from Gothenburg University and is now Professor Emeritus of Molecular Biotechnology at Linköping University. He has a life-long experience in biochemical research and development with positions at Umeå University and University of California, Riverside, CA, apart from Linköping University.
Bengt-Harald has served as board member of Glycobond since 2011.